Subscribe

ALK Gene Rearrangement and PD-L1 Expression

Videos - Lung Cancer
Edward Garon, MD
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Related Items
Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC
Web Exclusives published on May 18, 2020 in FDA Approvals, Lung Cancer
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Lung Cancer
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Lung Cancer
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Yvette Florio Lane
Web Exclusives published on March 22, 2019 in FDA Approvals, In the News, Lung Cancer
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer
Wayne Kuznar
August 2018 Vol 11, Special Issue published on August 20, 2018 in Lung Cancer
Last modified: April 27, 2017
Copyright © Engage Healthcare Communications, LLC. All rights reserved.